Bone marrow aspiration enhances detection of leukemia cells

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 11
Volume 18
Issue 11

Scientists in New Mexico are experimenting with a nanotechnology device that quantifies the amount of nanoparticle-bound tumor cells in a tissue sample and offers increased sensitivity to minimal residual disease (Cancer Res 69:6839-6847, 2009).

Scientists in New Mexico are experimenting with a nanotechnology device that quantifies the amount of nanoparticle-bound tumor cells in a tissue sample and offers increased sensitivity to minimal residual disease (Cancer Res 69:6839-6847, 2009).

The marrow biopsy needle targets tumor cells with nanoparticles and then preferentially extracts the cells with a magnetic needle. The group used anti-CD34 antibody loaded magnetic nanoparticles to detect CD34-positive cells as an indicator of leukemia. To quantify the cells recovered, they coupled this nanoparticle-mediated fishing for leukemic cells with the Superconducting Quantum Interference Device (SQUID).

The work is a collaborative effort between Senior Scientific and the University of New Mexico Health Science Center, both in Albuquerque.

Recent Videos
Approximately 95% of those with a complete response to enfortumab vedotin plus pembrolizumab were alive after 2 years in the phase 3 EV-302 trial.
According to Megan Mullins, PhD, MPH, challenging cultural norms surrounding death and dying may reduce the receipt of low-value end-of-life cancer care.
Thomas Powles, MBBS, MRCP, MD, highlighted fatigue, nausea, and peripheral neuropathy as toxicities observed with enfortumab vedotin plus pembrolizumab.
Earlier and more frequent talks about disabling ICDs with patients receiving end-of-life care and their families may help avoid excessive pain.
3 experts in this video
3 experts in this video
Large international meetings may facilitate conversations regarding disparities of care outside of high-income countries.
Related Content